TrialInternational journal of hematology2019

Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.

Takeshi Takahashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.